drug · small molecule

REVUFORJ

updated 5mo ago

by $SNDX Syndax Pharmaceuticals Inc🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for leukemia and 1 investigational indication.

targets

Menin

all catalysts(0)

nothing on the calendar yet

News(2)

Kura spins diabetes work into a Lilly-backed biotech startup
Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
biopharma_dive · 24d ago
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.
fiercebiotech · 24d ago

brand

REVUFORJ

trade names

Revuforj

generic

REVUMENIB CITRATE

MOA

12.1 Mechanism of Action Revumenib is a menin inhibitor that blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of wild-type KMT2A or KMT2A fusion proteins with menin is involved in NPM1 mutated acute myeloid leukemias and KMT2A - rearranged acute leukemias, respectively, through activation of a leukemogenic transcriptional pathway. Susceptible NPM1 mutations are defined as those that result in loss of the nucleolar localization signal and the insertion of a new nuclear export signal leading to the accumulation of mutant NPM1 in the cytoplasm of AML cells. The most common of such NPM1 mutations in patients with AML are Types A, B, and D. In nonclinical studies using cells that express KMT2A fusions, inhibition of the menin-KMT2A interaction with revumenib altered the transcription of multiple genes including differentiation markers. In nonclinical in vitro and in vivo studies, revumenib demonstrated antiproliferative and antitumor activity in leukemia cells harboring KMT2A fusion proteins. Revumenib also showed antiproliferative activity in vitro in leukemia cells with an NPM1 mutation.

indication

1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. ( 1 ) the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. ( 1 ) Relapsed or Refractory Acute Leukemia REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older. REVUFORJ is indicated for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1 ) mutation [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , and Clinical Studies (14.1) ] in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(2)

Kura spins diabetes work into a Lilly-backed biotech startup

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

biopharma_dive · 24d ago

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment.

fiercebiotech · 24d ago

REVUFORJ

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)

REVUFORJ

🐶 often sniffed alongside

targets

all catalysts(0)

News(2)

Report a data issue

comments(0)